During the recent session, Relay Therapeutics Inc (NASDAQ:RLAY)’s traded shares were 0.68 million, with the beta value of the company hitting 1.64. At the last check today, the stock’s price was $4.74, reflecting an intraday loss of -3.66% or -$0.18. The 52-week high for the RLAY share is $11.16, that puts it down -135.44 from that peak though still a striking 26.16% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $793.39M, and the average intraday trading volume over the past 10 days was 3.88 million shares, and the average trade volume was 2.31 million shares over the past three months.
Relay Therapeutics Inc (RLAY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.23. RLAY has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.55.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
Relay Therapeutics Inc (RLAY) registered a -3.66% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.66% in intraday trading to $4.74, hitting a weekly high. The stock’s 5-day price performance is 24.41%, and it has moved by 11.27% in 30 days. Based on these gigs, the overall price performance for the year is -53.62%. The short interest in Relay Therapeutics Inc (NASDAQ:RLAY) is 14.95 million shares and it means that shorts have 5.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies an increase of 73.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16 and $20 respectively. As a result, RLAY is trading at a discount of -321.94% off the target high and -237.55% off the low.
Relay Therapeutics Inc (RLAY) estimates and forecasts
Statistics show that Relay Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Relay Therapeutics Inc (RLAY) shares have gone down -50.00% during the last six months, with a year-to-date growth rate less than the industry average at 8.60% against 16.90. In the rating firms’ projections, revenue will decrease -40.98% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.08M as predicted by 10 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 50k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -38.74%. While earnings are projected to return 9.80% in 2025.
RLAY Dividends
Relay Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
Relay Therapeutics Inc insiders own 1.71% of total outstanding shares while institutional holders control 98.37%, with the float percentage being 100.09%. SB INVESTMENT ADVISERS (UK) LTD is the largest shareholder of the company, while 272.0 institutions own stock in it. As of 2024-06-30, the company held over 27.9 million shares (or 21.0093% of all shares), a total value of $181.94 million in shares.
The next largest institutional holding, with 11.7 million shares, is of VANGUARD GROUP INC’s that is approximately 8.8125% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $76.32 million.
Also, the Mutual Funds coming in first place with the largest holdings of Relay Therapeutics Inc (RLAY) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 4.89 shares. This amounts to just over 2.92 percent of the company’s overall shares, with a $23.3 million market value. The same data shows that the other fund manager holds slightly less at 3.87, or about 2.31% of the stock, which is worth about $18.44 million.
